Transfection of follicular thyroid cancer cells with thyrotropin receptor cDNA alleviates malignant phenotype in vitro and in vivo

2002 ◽  
Vol 38 ◽  
pp. S88
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Thyrotropin Receptor ◽  
Follicular Thyroid Cancer ◽  
Malignant Phenotype ◽  
Receptor Cdna ◽  
Thyroid Cancer Cells

Functional Thyrotropin Receptor Attenuates Malignant Phenotype of Follicular Thyroid Cancer Cells

Endocrine ◽  
2006 ◽  
Vol 30 (1) ◽  
pp. 129-138 ◽  
Author(s):  
S. Hoffmann ◽  
K. Maschuw ◽  
I. Hassan ◽  
A. Wunderlich ◽  
S. Lingelbach ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Thyrotropin Receptor ◽  
Follicular Thyroid Cancer ◽  
Malignant Phenotype ◽  
Thyroid Cancer Cells

scholarly journals Combinatorial Antitumor Effect of Rapamycin andβ-Elemene in Follicular Thyroid Cancer Cells

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Jun Zhou ◽  
Li-Li He ◽  
Xiao-Fei Ding ◽  
Qiu-Qi Yuan ◽  
Jian-Xin Zhang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Antitumor Effect ◽  
Mtor Inhibitor ◽  
Objective Response ◽  
Underlying Mechanism ◽  
Follicular Thyroid Cancer ◽  
Thyroid Cancer Cells

Background.mTOR signaling would be a promising target for thyroid cancer therapy. However, in clinical trials, objective response rate with mTOR inhibitor monotherapy in most cancer types was modest. A new focus on development of combinatorial strategies with rapalogs is increasing.Objective.Investigating the combinatorial antitumor effect of rapamycin andβ-elemene in follicular thyroid cancer cells.Methods.MTT assay was used to determine the FTC-133 cell proliferation after culturing with rapamycin and/orβ-elemene. To analyze their combinatorial effect, immunoblotting was performed to analyze the activation status of AKT. Moreover,β-elemene attenuated rapamycin-induced immunosuppression was tested in mice.Results.Combination of rapamycin andβ-elemene exerted significant synergistic antiproliferative effects in FTC-133 cell linesin vitro, based on inhibiting the AKT feedback activation induced by rapamycin.In vivo, theβ-elemene could attenuate rapamycin-induced immunosuppression via reversing imbalance of Treg/Th17, with the underlying mechanism needed to be declared.Conclusions. We demonstrate that the novel combination of mTOR inhibitor withβ-elemene synergistically attenuates tumor cell growth in follicular thyroid cancer, which requires additional preclinical validation.

scholarly journals Long Non-Coding RNA MAPK8IP1P2 Inhibits Lymphatic Metastasis of Thyroid Cancer by Activating Hippo Signaling via Sponging miR-146b-3p

2021 ◽  
Vol 10 ◽  
Author(s):  
Xiaoli Liu ◽  
Qingfeng Fu ◽  
Xuehai Bian ◽  
Yantao Fu ◽  
Jingwei Xin ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Lymphatic Metastasis ◽  
Inhibitory Effect ◽  
Hippo Signaling ◽  
Anoikis Resistance ◽  
Potential Biomarker ◽  
Thyroid Cancer Cells

The principal issue derived from thyroid cancer is its high propensity to metastasize to the lymph node. Aberrant exprssion of long non-coding RNAs have been extensively reported to be significantly correlated with lymphatic metastasis of thyroid cancer. However, the clinical significance and functional role of lncRNA-MAPK8IP1P2 in lymphatic metastasis of thyroid cancer remain unclear. Here, we reported that MAPK8IP1P2 was downregulated in thyroid cancer tissues with lymphatic metastasis. Upregulating MAPK8IP1P2 inhibited, while silencing MAPK8IP1P2 enhanced anoikis resistance in vitro and lymphatic metastasis of thyroid cancer cells in vivo. Mechanistically, MAPK8IP1P2 activated Hippo signaling by sponging miR-146b-3p to disrupt the inhibitory effect of miR-146b-3p on NF2, RASSF1, and RASSF5 expression, which further inhibited anoikis resistance and lymphatic metastasis in thyroid cancer. Importantly, miR-146b-3p mimics reversed the inhibitory effect of MAPK8IP1P2 overexpression on anoikis resistance of thyroid cancer cells. In conclusion, our findings suggest that MAPK8IP1P2 may serve as a potential biomarker to predict lymphatic metastasis in thyroid cancer, or a potential therapeutic target in lymphatic metastatic thyroid cancer.

scholarly journals Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo

2021 ◽  
Vol 5 (2) ◽  
pp. 143-154
Author(s):  
Le Xiong ◽  
Xiao-Min Lin ◽  
Jun-Hua Nie ◽  
Hai-Shan Ye ◽  
Jia Liu
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Anaplastic Thyroid Cancer ◽  
Thyroid Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document